Blue Shield

Public gets mixed messages regarding efficacy of Avastin for treating breast cancer

Health & Medicine

Late last week, the FDA ruled that Avastin could no longer be marketed as treatment for breast cancer. But Medicare and virtually all private insurance providers will continue to pay for just that use of the drug. It’s a mixed message that has raised some eyebrows.

Tell us about your experience accessing The World

We want to hear your feedback so we can keep improving our website, theworld.org. Please fill out this quick survey and let us know your thoughts (your answers will be anonymous). Thanks for your time!

We respect your time, attention and privacy

This is a news website, not a click casino. We do NOT employ deceptive behaviors, display annoying ads or use third party cookies and trackers to monetize your visit or help advertisers track you across the internet.

Simply, we ask that you would consider a donation to support the journalism we produce every weekday. Thank you.